Skip to main content

Table 1 Patient and tumor characteristics at baseline and their relationship with pCR

From: ER, PgR, Ki67, p27Kip1, and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab

  pCR non-pCR pCR rate (%) p-value
Menopausal status     
 Premenopausal 27 24 52.9  
 Postmenopausal 57 21 73.1 0.019*
Clinical tumor size     
 T1 4 2 66.7  
 T2 56 25 9.1  
 T3 15 11 57.7  
 T4 9 7 56.2 0.62
Clinical nodal status     
 N0 27 14 65.9  
 N1 39 20 66.1  
 N2 11 6 64.7  
 N3 7 5 58.3 0.96
Clinical stage     
 I 1 1 50.0  
 IIA 26 11 70.3  
 IIB 24 14 63.2  
 IIIA 19 10 65.5  
 IIIB 7 4 63.6  
 IIIC 7 5 58.3 0.97
Type of Taxanes     
 Paclitaxel 78 39 66.7  
 Docetaxe 6 6 50.0 0.40
HG     
 High (3) 77 33 70.0  
 Low (1–2) 7 12 41.2 0.005*
ER     
 Negative (<1 %) 66 18 78.6  
 Positive (≥1 %) 18 27 40.0 <0.001*
PgR     
 Negative (<1 %) 70 23 75.3  
 Positive (≥1 %) 14 22 38.9 <0.001*
Ki67     
 High (≥30 %) 67 26 72.0  
 Low (<30 %) 17 19 47.2 0.008*
p27Kip1     
 Low (<75 %) 66 27 71.0  
 High (≥75 %) 18 18 50.0 0.025*
  1. pCR, pathological complete response; HG, histological grade; ER, estrogen receptor; PgR, progesterone receptor
  2. *p < 0.05 was considered significant; all significant values are shown in bold